Clinical Trials Browser

Phase 2 × Epstein-Barr Virus Infections × 90 days × Clear all

NCT03258567 2026-06-05

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

Phase 2 Recruiting

Lymphoma, Lymphoproliferative Disorders, Epstein-Barr Virus Infections

NCT04554914 2026-04-27

A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases

Phase 2 Active not recruiting

LymphoidSarcoma

Immunologic Deficiency Syndromes, Leiomyosarcoma, Lymphoproliferative Disorders, Epstein-Barr Virus Infections